MP76-19 THE EFFICACY OF TRIGGER POINT INJECTIONS IN THE TREATMENT OF SEXUAL PAIN

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I1 Apr 2016MP76-19 THE EFFICACY OF TRIGGER POINT INJECTIONS IN THE TREATMENT OF SEXUAL PAIN Sonia Bahlani-Khanna, Alexandra King, and Robert Moldwin Sonia Bahlani-KhannaSonia Bahlani-Khanna More articles by this author , Alexandra KingAlexandra King More articles by this author , and Robert MoldwinRobert Moldwin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1870AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Chronic pelvic pain (CPP), including pelvic floor dysfunction (PFD) and Category III B prostatitis/ chronic pelvic pain (CP/CPPS), affects up to 40% of patients age 18-45 years. Patients often present with a combination of lower urinary tract symptoms with pelvic pain and sexual dysfunction. Sexual pain is found in up to 42% of women with CPP. No uniform treatment strategy exists for treating these patients. Often patients with PFD and CP/CPPS will have trigger points. These hyperirritable muscular foci can give rise to pain. Trigger points can be involved in the etiology of sexual pain in women and ejaculatory pain in men. Trigger point injections involve infiltration of the musculature with anesthetic solution (consisting of a mixture of lidocaine and marcaine), which can be both diagnostic and therapeutic for patients. These injections have been shown to be effective in treating patients with PFD and associated pain. The objective of this study was to further evaluate the role of trigger point injections in treatment of PFD and CP/CPPS, specifically in regards to sexual pain. METHODS 48 patients with PFD and CP/CPPS were identified via medical record review. Medical records with access to trigger point procedures and specific questions regarding post procedural symptomatology were reviewed. Results were recorded in a database. Categoric data were compared with the chi-square test; binary data were compared with the McNemar test. No data was considered censored. All analyses were performed using SPSS version 22.0. RESULTS 48 patients with PFD and CP/CPPS were included. Median age of patients was 47 years [43.1-52.5]. 36 (75%) of these patients are female and 12 (25%) patients are male. 31 patients (64.6%) that received trigger point injections reported improvement in quality of life measures, such as decreases in hesitancy, nocturia, and constipation (all p<0.0001). In total, 22/48 patients reported sexual pain. 12 of 19 female patients with sexual pain reported improvement in sexual pain, including dyspareunia post procedure (p<0.0001). 3 of 3 of male patients (100 %) with ejaculatory pain felt improvement in symptoms post-procedure (p=.25). 15/22 patients reported improvement in sexual pain including dyspareunia and ejaculatory pain (p<.0001). CONCLUSIONS The use of trigger point injections is associated with an overall improvement in quality of life measures and sexual pain in patients diagnosed with PFD and CP/CPPS. This is the first study to evaluate sexual pain in patients after trigger point injections. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1014 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Sonia Bahlani-Khanna More articles by this author Alexandra King More articles by this author Robert Moldwin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...